Should I Buy REPL? REPL 2026 Analysis

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.840

1 Day change

-4.76%

52 Week Range

13.240

Analysis Updated At

2026/03/06

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Replimune Group Inc (REPL) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. While the stock has potential upside in the next month, the lack of strong financial performance and recent insider or hedge fund activity makes it prudent to hold off on buying at this time.

Technical Analysis

The technical indicators for REPL are bearish. The MACD is below 0 and negatively expanding, RSI is neutral at 30.438, and moving averages suggest a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 7.737, with key support at 6.962 and resistance at 8.512.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market, but the high implied volatility (243.83) and IV percentile (86.45) suggest significant uncertainty and risk.

Technical Summary

Sell

Buy

Positive Catalysts

Piper Sandler raised the price target to $14 from $13 and maintained an Overweight rating. The upcoming April 10 PDUFA date for RP1 could act as a catalyst if the FDA decision is favorable.

Neutral/Negative Catalysts

The company's financials remain weak, with a net income loss of -$70.93M in Q3 2026 and a YoY EPS decline of -2.53%. Additionally, there are no recent news updates or significant insider or hedge fund activity to suggest strong near-term momentum.

Financial Performance

In Q3 2026, Replimune reported no revenue growth (0% YoY), a net income loss of -$70.93M (up 6.92% YoY), and a decline in EPS to -0.77 (-2.53% YoY). Gross margin remains at 0%. The financials suggest the company is still in a growth phase with no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is cautiously optimistic. Piper Sandler raised the price target to $14 and maintained an Overweight rating, citing compelling analyses addressing FDA concerns. However, the approval decision for RP1 still carries risk.

7 Analyst Rating

Wall Street analysts forecast REPL stock price to rise

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 8.230

Low

Averages

11.43

High

Current: 8.230

Low

Averages

11.43

High

Piper Sandler

Overweight

maintain

$13 -> $14

AI Analysis

2026-02-05

Reason

Piper Sandler

Price Target

$13 -> $14

AI Analysis

2026-02-05

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Replimune to $14 from $13 and keeps an Overweight rating on the shares following Q3 reporting and ahead of RP1's April 10 PDUFA date. Replimune has felt the full brunt of the impact of FDA turmoil and seemingly capricious decision-making in recent months, Piper notes. The firm understands that additional analyses addressing FDA's concern around the contribution of components in the single-arm IGNYTE trial played a key role in this apparent about-face, and finds these recently disclosed analyses compelling. While Piper acknowledges that RP1's approval decision still carries risk, it's the firm's sense that FDA wouldn't have accepted the resubmission with the intent of rejecting it a second time.

BMO Capital

Evan Seigerman

Underperform

Market Perform

upgrade

$2 -> $11

2025-11-03

Reason

BMO Capital

Evan Seigerman

Price Target

$2 -> $11

2025-11-03

upgrade

Underperform

Market Perform

Reason

BMO Capital analyst Evan Seigerman upgraded Replimune to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels "reflect appropriate risk" for the company's RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune's "productive" Type A meeting supports potential approval.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REPL

Unlock Now

REPL Should I Buy

REPL Should I Buy

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch